Processus Dégénératifs, Stress et Vieillissement

 

Sélection de publications

1/  Baloula V, Fructuoso M, Kassis N, Gueddouri D, Paul JL, Janel N. Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia. Redox Biol. 2018 Oct;19:200-209.

2/ Palandri A, Martin E, Russi M, Rera M, Tricoire H, Monnier V. Identification of cardioprotective drugs by medium-scale in vivo pharmacological screening on a Drosophila cardiac model of Friedreich’s ataxia. Dis Model Mech. 2018 Jul 20;11(7).

3/ Sowa AS, Martin E, Martins IM, Schmidt J, Depping R, Weber JJ, Rother F, Hartmann E, Bader M, Riess O, Tricoire H, Schmidt T. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3. Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2624-E2633

4/ Janel N, Alexopoulos P, Badel A, Lamari F, Camproux AC, Lagarde J, Simon S, Feraudet-Tarisse C, Lamourette P, Arbones M, Paul JL, Dubois B, Potier MC, Sarazin M, Delabar JM. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease. Transl Psychiatry. 2017 Jun 20;7(6):e1154.

5/ de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jul;15(8):801-10

 

Publications indexées dans PubMed (depuis 2014)

Palandri A, Martin E, Russi M, Rera M, Tricoire H, Monnier V. Identification of cardioprotective drugs by medium-scale in vivo pharmacological screening on a Drosophila cardiac model of Friedreich’s ataxia. Dis Model Mech. 2018 Jul 20;11(7).

Sowa AS, Martin E, Martins IM, Schmidt J, Depping R, Weber JJ, Rother F, Hartmann E, Bader M, Riess O, Tricoire H, Schmidt T. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3. Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2624-E2633.

London J, Ndiaye FK, Bui LC, Souchet B, Daubigney F, Magnan C, Luquet S, Dairou J, Janel N, Rouch C. Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain. Mol Neurobiol. 2018 Sep 20.

Baloula V, Fructuoso M, Kassis N, Gueddouri D, Paul JL, Janel N. Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia. Redox Biol. 2018 Oct;19:200-209.

Latour A, Gu Y, Kassis N, Daubigney F, Colin C, Gausserès B, Middendorp S, Paul JL, Hindié V, Rain JC, Delabar JM, Yu E, Arbones M, Mallat M, Janel N. LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice. Mol Neurobiol. 2018 May 30.

Fructuoso M, Rachdi L, Philippe E, Denis RG, Magnan C, Le Stunff H, Janel N, Dierssen M. Corrigendum to « Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome » [Free Radic. Biol. Med. 114 (2018) 122-130]. Free Radic Biol Med. 2018 Apr;118:150.

Fructuoso M, Rachdi L, Philippe E, Denis RG, Magnan C, Le Stunff H, Janel N, Dierssen M. Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome. Free Radic Biol Med. 2018 Jan;114:122-130.

London J, Rouch C, Bui LC, Assayag E, Souchet B, Daubigney F, Medjaoui H, Luquet S, Magnan C, Delabar JM, Dairou J, Janel N. Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues. Mol Neurobiol. 2018 May;55(5):3822-3831.

Janel N, Alexopoulos P, Badel A, Lamari F, Camproux AC, Lagarde J, Simon S, Feraudet-Tarisse C, Lamourette P, Arbones M, Paul JL, Dubois B, Potier MC, Sarazin M, Delabar JM. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease. Transl Psychiatry. 2017 Jun 20;7(6):e1154.

Haddadi-Guemghar H, Tlili A, Dairou J, Paul JL, Madani K, Janel N. Effect of lyophilized prune extract on hyperhomocysteinemia in mice. Food Chem Toxicol. 2017 May;103:183-187.

Ragheb R, Chuyen A, Torres M, Defaye A, Seyres D, Kremmer L, Fernandez-Nunez N, Tricoire H, Rihet P, Nguyen C, Röder L, Perrin L. Interplay between trauma and Pseudomonas entomophila infection in flies: a central role of the JNK pathway and of CrebA. Sci Rep. 2017 Nov 24;7(1):16222.

de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jul;15(8):801-10.

Yefsah-Idres A, Benazzoug Y, Otman A, Latour A, Middendorp S, Janel N. Hepatoprotective effects of lycopene on liver enzymes involved in methionine and xenobiotic metabolism in hyperhomocysteinemic rats. Food Funct. 2016 Jun 15;7(6):2862-9.

Créau N, Cabet E, Daubigney F, Souchet B, Bennaï S, Delabar J. Specific age-related molecular alterations in the cerebellum of Down syndrome mouse models. Brain Res. 2016 Jun 10.

Ramambason C, Moroy G, Daubigney F, Paul JL, Janel N. Effect of cadmium administration in hyperhomocysteinemic mice due to cystathionine beta synthase deficiency. Exp Toxicol Pathol. 2016 Jun;68(6):365-70.

Renon M, Legrand B, Blanc E, Daubigney F, Bokobza C, Mortreux M, Paul JL, Delabar JM, Rouach H, Andreau K, Janel N. Impact of Dyrk1A level on alcohol metabolism. Biochim Biophys Acta. 2016 May 20;1862(9):1495-1503.

Dambroise E, Monnier L, Ruisheng L, Aguilaniu H, Joly JS, Tricoire H, Rera M. Two phases of aging separated by the Smurf transition as a public path to death. Sci Rep. 2016 Mar 22;6:23523.

Tricoire H, Rera M. A New, Discontinuous 2 Phases of Aging Model: Lessons from Drosophila melanogaster. PLoS One. 2015 Nov 3;10(11):e0141920.

Lovera-Leroux M, Crobeddu B, Kassis N, Petit PX, Janel N, Baeza-Squiban A, Andreau K. The iron component of particulate matter is antiapoptotic: A clue to the development of lung cancer after exposure to atmospheric pollutants? Biochimie. 2015 Nov;118:195-206.

Souchet B, Guedj F, Penke-Verdier Z, Daubigney F, Duchon A, Herault Y, Bizot JC, Janel N, Créau N, Delatour B, Delabar JM. Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models. Front Behav Neurosci. 2015 Oct 20;9:267.

Bartesaghi R, Haydar TF, Delabar JM, Dierssen M, Martínez-Cué C, Bianchi DW. New Perspectives for the Rescue of Cognitive Disability in Down Syndrome. J Neurosci. 2015 Oct 14;35(41):13843-52.

Palandri A, L’hôte D, Cohen-Tannoudji J, Tricoire H, Monnier V. Frataxin inactivation leads to steroid deficiency in flies and human ovarian cells. Hum Mol Genet. 2015 May 1;24(9):2615-26.

Heidari R, Monnier V, Martin E, Tricoire H. Methylene Blue Partially Rescues Heart Defects in a Drosophila Model of Huntington’s Disease. J Huntingtons Dis. 2015;4(2):173-86.

Kariyawasam D, Rachdi L, Carré A, Martin M, Houlier M, Janel N, Delabar JM, Scharfmann R, Polak M. DYRK1A BAC transgenic mouse: a new model of thyroid dysgenesis in Down syndrome. Endocrinology. 2015 Mar;156(3):1171-80.

Bouleau S, Tricoire H. Drosophila models of Alzheimer’s disease: advances, limits, and perspectives. J Alzheimers Dis. 2015;45(4):1015-38.

Souchet B, Latour A, Gu Y, Daubigney F, Paul JL, Delabar JM, Janel N. Molecular rescue of DYRK1A overexpression in cystathionine beta synthase-deficient mouse brain by enriched environment combined with voluntary exercise. J Mol Neurosci. 2015 Feb;55(2):318-23.

Seguin A, Monnier V, Palandri A, Bihel F, Rera M, Schmitt M, Camadro JM, Tricoire H, Lesuisse E. A Yeast/Drosophila Screen to Identify New Compounds Overcoming Frataxin Deficiency. Oxid Med Cell Longev. 2015;2015:565140.

Delabar JM, Latour A, Noll C, Renon M, Salameh S, Paul JL, Arbones M, Movassat J, Janel N. One-carbon cycle alterations induced by Dyrk1a dosage. Mol Genet Metab Rep. 2014 Nov 21;1:487-492.

Souchet B, Guedj F, Sahún I, Duchon A, Daubigney F, Badel A, Yanagawa Y, Barallobre MJ, Dierssen M, Yu E, Herault Y, Arbones M, Janel N, Créau N, Delabar JM. Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage. Neurobiol Dis. 2014 Sep;69:65-75.

Janel N, Sarazin M, Corlier F, Corne H, de Souza LC, Hamelin L, Aka A, Lagarde J, Blehaut H, Hindié V, Rain JC, Arbones ML, Dubois B, Potier MC, Bottlaender M, Delabar JM. Plasma DYRK1A as a novel risk factor for Alzheimer’s disease. Transl Psychiatry. 2014 Aug 12;4:e425.

Rachdi L, Kariyawasam D, Aïello V, Herault Y, Janel N, Delabar JM, Polak M, Scharfmann R. Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance. Cell Cycle. 2014;13(14):2221-9.

Barallobre MJ, Perier C, Bové J, Laguna A, Delabar JM, Vila M, Arbonés ML. DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson’s disease. Cell Death Dis. 2014 Jun 12;5:e1289.

Rachdi L, Kariyawasam D, Guez F, Aïello V, Arbonés ML, Janel N, Delabar JM, Polak M, Scharfmann R. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia. 2014 May;57(5):960-9.

Guedj F, Bianchi DW, Delabar JM. Prenatal treatment of Down syndrome: a reality? Curr Opin Obstet Gynecol. 2014 Apr;26(2):92-103.

Mouton-Liger F, Sahún I, Collin T, Lopes Pereira P, Masini D, Thomas S, Paly E, Luilier S, Même S, Jouhault Q, Bennaï S, Beloeil JC, Bizot JC, Hérault Y, Dierssen M, Créau N. Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: implications for Down syndrome. Neurobiol Dis. 2014 Mar;63:92-106.

Bui LC, Tabouy L, Busi F, Dupret JM, Janel N, Planque C, Delabar JM, Rodrigues-Lima F, Dairou J. A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase. Anal Biochem. 2014 Mar 15;449:172-8.

De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, Dierssen M. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2014 Feb;58(2):278-88.

Tricoire H, Palandri A, Bourdais A, Camadro JM, Monnier V. Methylene blue rescues heart defects in a Drosophila model of Friedreich’s ataxia. Hum Mol Genet. 2014 Feb 15;23(4):968-79.

Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedj F, Janel N, Chavis P, Delabar J, Manzoni OJ. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. J Neurosci. 2014 Jan 22;34(4):1138-47.

Gourdain S, Dairou J, Denhez C, Bui LC, Rodrigues-Lima F, Janel N, Delabar JM, Cariou K, Dodd RH. Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity. J Med Chem. 2013 Dec 12;56(23):9569-85.

Tlili A, Noll C, Middendorp S, Duchon A, Jouan M, Benabou E, Hérault Y, Paul JL, Delabar JM, Janel N. DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels. Mol Genet Metab. 2013 Nov;110(3):371-7.

Sailani MR, Makrythanasis P, Valsesia A, Santoni FA, Deutsch S, Popadin K, Borel C, Migliavacca E, Sharp AJ, Duriaux Sail G, Falconnet E, Rabionet K, Serra-Juhé C, Vicari S, Laux D, Grattau Y, Dembour G, Megarbane A, Touraine R, Stora S, Kitsiou S, Fryssira H, Chatzisevastou-Loukidou C, Kanavakis E, Merla G, Bonnet D, Pérez-Jurado LA, Estivill X, Delabar JM, Antonarakis SE. The complex SNP and CNV genetic architecture of the increased risk of congenital heart defects in Down syndrome. Genome Res. 2013 Sep;23(9):1410-21.

Laguna A, Barallobre MJ, Marchena MÁ, Mateus C, Ramírez E, Martínez-Cue C, Delabar JM, Castelo-Branco M, de la Villa P, Arbonés ML. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome. Hum Mol Genet. 2013 Jul 15;22(14):2775-84.

Tlili A, Jacobs F, de Koning L, Mohamed S, Bui LC, Dairou J, Belin N, Ducros V, Dubois T, Paul JL, Delabar JM, De Geest B, Janel N. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice. Biochim Biophys Acta. 2013 Jun;1832(6):718-28.

Ripoll C, Dairou J, Stora S, Delabar JM, Janel N. Plasma nitrate levels are increased in adult Down syndrome patients. Biomarkers. 2013 Jun;18(4):373-4.

Planque C, Dairou J, Noll C, Bui LC, Ripoll C, Guedj F, Delabar JM, Janel N. Mice deficient in cystathionine beta synthase display increased Dyrk1A and SAHH activities in brain. J Mol Neurosci. 2013 May;50(1):1-6.

Noll C, Lameth J, Paul JL, Janel N. Effect of catechin/epicatechin dietary intake on endothelial dysfunction biomarkers and proinflammatory cytokines in aorta of hyperhomocysteinemic mice. Eur J Nutr. 2013 Apr;52(3):1243-50.

Abekhoukh S, Planque C, Ripoll C, Urbaniak P, Paul JL, Delabar JM, Janel N. Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in the brain of hyperhomocysteinemic mice. Mol Neurobiol. 2013 Feb;47(1):105-16.

Monnier V, Iché-Torres M, Rera M, Contremoulins V, Guichard C, Lalevée N, Tricoire H, Perrin L. dJun and Vri/dNFIL3 are major regulators of cardiac aging in Drosophila. PLoS Genet. 2012;8(11):e1003081.

Régnier V, Billard JM, Gupta S, Potier B, Woerner S, Paly E, Ledru A, David S, Luilier S, Bizot JC, Vacano G, Kraus JP, Patterson D, Kruger WD, Delabar JM, London J. Brain phenotype of transgenic mice overexpressing cystathionine β-synthase. PLoS One. 2012;7(1):e29056.

Tlili A, Hoischen A, Ripoll C, Benabou E, Badel A, Ronan A, Touraine R, Grattau Y, Stora S, van Bon B, de Vries B, Menten B, Bockaert N, Gecz J, Antonarakis SE, Campion D, Potier MC, Bléhaut H, Delabar JM, Janel N. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients. Mol Neurobiol. 2012 Oct;46(2):297-303.

Petrakis S, Raskó T, Russ J, Friedrich RP, Stroedicke M, Riechers SP, Muehlenberg K, Möller A, Reinhardt A, Vinayagam A, Schaefer MH, Boutros M, Tricoire H, Andrade-Navarro MA, Wanker EE. Identification of human proteins that modify misfolding and proteotoxicity of pathogenic ataxin-1. PLoS Genet. 2012;8(8):e1002897.

Cossec JC, Lavaur J, Berman DE, Rivals I, Hoischen A, Stora S, Ripoll C, Mircher C, Grattau Y, Olivomarin JC, de Chaumont F, Lecourtois M, Antonarakis SE, Veltman JA, Delabar JM, Duyckaerts C, Di Paolo G, Potier MC. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum Mol Genet. 2012 Jul 15;21(14):3156-72.

Guedj F, Pereira PL, Najas S, Barallobre MJ, Chabert C, Souchet B, Sebrie C, Verney C, Herault Y, Arbones M, Delabar JM. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol Dis. 2012 Apr;46(1):190-203.

Noll C, Tlili A, Ripoll C, Mallet L, Paul JL, Delabar JM, Janel N. Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism. Mol Genet Metab. 2012 Mar;105(3):484-8.

Créau N. Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics. Neural Plast. 2012;2012:171639.

Ripoll C, Rivals I, Ait Yahya-Graison E, Dauphinot L, Paly E, Mircher C, Ravel A, Grattau Y, Bléhaut H, Mégarbane A, Dembour G, de Fréminville B, Touraine R, Créau N, Potier MC, Delabar JM. Molecular signatures of cardiac defects in Down syndrome lymphoblastoid cell lines suggest altered ciliome and Hedgehog pathways. PLoS One. 2012;7(8):e41616.

Attar H, Bedard K, Migliavacca E, Gagnebin M, Dupré Y, Descombes P, Borel C, Deutsch S, Prokisch H, Meitinger T, Mehta D, Wichmann E, Delabar JM, Dermitzakis ET, Krause KH, Antonarakis SE. Extensive natural variation for cellular hydrogen peroxide release is genetically controlled. PLoS One. 2012;7(8):e43566.

Reinhardt A, Feuillette S, Cassar M, Callens C, Thomassin H, Birman S, Lecourtois M, Antoniewski C, Tricoire H. Lack of miRNA Misregulation at Early Pathological Stages in Drosophila Neurodegenerative Disease Models. Front Genet. 2012 Oct 30;3:226.